{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:08:59Z","timestamp":1792177739751,"version":"4.4.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,9,29]],"date-time":"2017-09-29T00:00:00Z","timestamp":1506643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Alfresa Pharma Corporation"},{"DOI":"10.13039\/100015990","name":"Sanofi K.K.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015990","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.yebeh.2017.09.010","type":"journal-article","created":{"date-parts":[[2017,12,22]],"date-time":"2017-12-22T15:01:20Z","timestamp":1513954880000},"page":"134-141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Efficacy and safety of vigabatrin in Japanese patients with infantile spasms: Primary short-term study and extension study"],"prefix":"10.1016","volume":"78","author":[{"given":"Yoko","family":"Ohtsuka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2017.09.010_bb0005","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1528-1167.2010.02522.x","article-title":"Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005\u20132009","volume":"51","author":"Berg","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.09.010_bb0010","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1212\/WNL.0b013e318259e2cf","article-title":"Evidence-based guideline update: medical treatment of infantile spasms report of the guideline development subcommittee of the American academy of neurology and the practice committee of the child neurology society","volume":"78","author":"Go","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2017.09.010_bb0015","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1111\/j.1528-1167.2010.02657.x","article-title":"Infantile spasms: a U.S. consensus report","volume":"51","author":"Pellock","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.09.010_bb0020","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.braindev.2015.05.012","article-title":"Predictive factors for relapse of epileptic spasms after adrenocorticotropic hormone therapy in West syndrome","volume":"38","author":"Hayashi","year":"2016","journal-title":"Brain Dev"},{"key":"10.1016\/j.yebeh.2017.09.010_bb0025","doi-asserted-by":"crossref","first-page":"199","DOI":"10.4137\/JCNSD.S6371","article-title":"Safety and efficacy of vigabatrin for the treatment of infantile spasms","volume":"3","author":"Faulkner","year":"2011","journal-title":"J Cent Nerv Syst Dis"},{"key":"10.1016\/j.yebeh.2017.09.010_bb0030","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1111\/j.1528-1167.2010.02718.x","article-title":"The Japanese scheme of ACTH therapy in West syndrome","volume":"51","author":"Fukuyama","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.09.010_bb0035","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/epi.13057","article-title":"Summary of recommendations for the management of infantile seizures: Task Force Report for the ILAE Commission of Pediatrics","volume":"56","author":"Wilmshurst","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.09.010_bb0040","author":"National Institute for Health and Care Excellence"},{"key":"10.1016\/j.yebeh.2017.09.010_bb0045","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1111\/j.1528-1167.2008.01589.x","article-title":"Vigabatrin in the treatment of childhood epilepsy: a retrospective chart review of efficacy and safety profile","volume":"49","author":"Camposano","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.09.010_bb0050","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1600-0404.2011.01599.x","article-title":"Vigabatrin therapy for infantile spasms: review of major trials in Europe, Canada, and the United States; and recommendations for dosing","volume":"124","author":"Carmant","year":"2011","journal-title":"Acta Neurol Scand Suppl"},{"key":"10.1016\/j.yebeh.2017.09.010_bb0055","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1528-1167.2008.01988.x","article-title":"Vigabatrin: 2008 update","volume":"50","author":"Willmore","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.09.010_bb0060","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ana.21526","article-title":"Taurine deficiency is a cause of vigabatrin-induced retinal phototoxicity","volume":"65","author":"Jammoul","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1016\/j.yebeh.2017.09.010_bb0065","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1535-7511.2009.01315.x","article-title":"Evaluating risks for vigabatrin treatment","volume":"9","author":"Krauss","year":"2009","journal-title":"Epilepsy Curr"},{"key":"10.1016\/j.yebeh.2017.09.010_bb0070","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ijpharm.2014.07.023","article-title":"The anti-epileptic drug substance vigabatrin inhibits taurine transport in intestinal and renal cell culture models","volume":"473","author":"Plum","year":"2014","journal-title":"Int J Pharm"},{"key":"10.1016\/j.yebeh.2017.09.010_bb0075","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/dmcn.12573","article-title":"Does vigabatrin treatment for infantile spasms cause visual field defects? An international multicentre study","volume":"57","author":"Riikonen","year":"2015","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.yebeh.2017.09.010_bb0080","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1212\/WNL.0000000000001069","article-title":"Vigabatrin retinal toxicity in children with infantile spasms: an observational cohort study","volume":"83","author":"Westall","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2017.09.010_bb0085","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1528-1167.2008.01728.x","article-title":"Cerebral MRI abnormalities associated with vigabatrin therapy","volume":"50","author":"Pearl","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.09.010_bb0090","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1111\/j.1528-1167.2010.02564.x","article-title":"Vigabatrin-associated reversible MRI signal changes in patients with infantile spasms","volume":"51","author":"Dracopoulos","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.09.010_bb0095","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1528-1167.2008.01961.x","article-title":"Visual fields at school-age in children treated with vigabatrin in infancy","volume":"50","author":"Gaily","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.09.010_bb0100","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1528-1157.1989.tb05316.x","article-title":"Proposal for revised classification of epilepsies and epileptic syndromes","volume":"30","author":"Commission on Classification and Terminology of the International League Against Epilepsy","year":"1989","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.09.010_bb0105","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S1059-1311(98)80021-6","article-title":"Long-term follow-up study of vigabatrin in pretreated children with West syndrome","volume":"7","author":"Siemes","year":"1998","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2017.09.010_bb0110","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1212\/01.WNL.0000127773.72699.C8","article-title":"Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society","volume":"62","author":"Mackay","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2017.09.010_bb0115","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/epi.13050","article-title":"Epilepsy in children with tuberous sclerosis complex: chance of remission and response to antiepileptic drugs","volume":"56","author":"Overwater","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.09.010_bb0120","first-page":"260","article-title":"Management of infantile spasms","volume":"4","author":"Nelson","year":"2015","journal-title":"Transl Pediatr"},{"key":"10.1016\/j.yebeh.2017.09.010_bb0125","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.yebeh.2016.01.012","article-title":"A lack of clinically apparent vision loss among patients treated with vigabatrin with infantile spasms: the UCLA experience","volume":"57","author":"Schwarz","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2017.09.010_bb0130","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S1474-4422(05)70199-X","article-title":"The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14months: a multicentre randomised trial","volume":"4","author":"Lux","year":"2005","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2017.09.010_bb0135","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1111\/epi.12847","article-title":"Long-term outcome in children with infantile spasms treated with vigabatrin: a cohort of 180 patients","volume":"55","author":"Djuric","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.09.010_bb0140","first-page":"444","article-title":"Effectiveness of vigabatrin in West syndrome associated with tuberous sclerosis","volume":"42","author":"Ando","year":"2010","journal-title":"No To Hattatsu"},{"key":"10.1016\/j.yebeh.2017.09.010_bb0145","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1528-1167.2008.01896.x","article-title":"Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy","volume":"50","author":"Wheless","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.09.010_bb0150","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0387-7604(81)80005-8","article-title":"Apparent brain atrophy and subdural hematoma following ACTH therapy","volume":"3","author":"Hara","year":"1981","journal-title":"Brain Dev"},{"key":"10.1016\/j.yebeh.2017.09.010_bb0155","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1528-1157.1992.tb02320.x","article-title":"Magnetic resonance imaging in infantile spasms: effects of hormonal therapy","volume":"33","author":"Konishi","year":"1992","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2017.09.010_bb0160","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1212\/WNL.54.12.2346-a","article-title":"Subdural hematoma during low-dose ACTH therapy in patients with West syndrome","volume":"54","author":"Ito","year":"2000","journal-title":"Neurology"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505017304729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505017304729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:26:01Z","timestamp":1761503161000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505017304729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":32,"alternative-id":["S1525505017304729"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2017.09.010","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of vigabatrin in Japanese patients with infantile spasms: Primary short-term study and extension study","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2017.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Author. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}